Crossmark

Identification of a protective microglial state mediated by miR-155 and interferon-γ signaling in a mouse model of Alzheimer’s disease

Crossref DOI link: https://doi.org/10.1038/s41593-023-01355-y

Published Online: 2023-06-08

Published Print: 2023-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yin, Zhuoran

Herron, Shawn

Silveira, Sebastian

Kleemann, Kilian http://orcid.org/0000-0002-2753-6804
Gauthier, Christian

Mallah, Dania

Cheng, Yiran http://orcid.org/0000-0001-5589-2024
Margeta, Milica A.

Pitts, Kristen M. http://orcid.org/0000-0001-7049-0883
Barry, Jen-Li

Subramanian, Ayshwarya http://orcid.org/0000-0002-4134-7612
Shorey, Hannah

Brandao, Wesley

Durao, Ana

Delpech, Jean-Christophe

Madore, Charlotte

Jedrychowski, Mark

Ajay, Amrendra K. http://orcid.org/0000-0003-2790-5726
Murugaiyan, Gopal

Hersh, Samuel W.

Ikezu, Seiko

Ikezu, Tsuneya http://orcid.org/0000-0002-3979-8596
Butovsky, Oleg http://orcid.org/0000-0003-0186-8867
Funding

Funding for this research was provided by:

U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01AG054672, R01AG051812, R01AG075509, R21AG076982, R41AG073059, R01AG054672, R01AG054672, R01AG054672, R01AG054672, R01AG054672, R01AG054672, R41AG073059, R01AG054672, R01AG054672, R01AG054672, R01AG054672, R01AG054672, R01AG054672, R01AG054672, R01AG054672, R01AG054672, RF1AG054199, R01AG066429, R01AG072719, R01AG067763, R41AG073059, R01AG075509)

U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01NS088137)

U.S. Department of Health & Human Services | NIH | National Eye Institute (R01EY027921, K12 EY016335, K08 EY030160, K12 EY016335, K08 EY030160)

BrightFocus Foundation (2020A016806)

Cure Alzheimer’s Fund (APOE consortium, APOE consortium)

U.S. Department of Health & Human Services | National Institutes of Health (F31AG071106, T32GM008541)

Research to Prevent Blindness Career Development Award.
License Information

Text and Data Mining valid from 2023-06-08

Version of Record valid from 2023-06-08
More Information

Article History

Received: 25 April 2022

Accepted: 5 May 2023

First Online: 8 June 2023

Competing interests

: O.B. is an inventor of a patent for the use of miR-155 inhibitors for the treatment of neurodegenerative diseases. O.B. collaborated with GSK and Regulus Therapeutics, received research funding from Sanofi and GSK, has received honoraria for lectures from and has provided consultancy services to Camp4 and Ono Pharma USA. T.I. consults Takeda. The remaining authors declare no competing interests.

Document is current

Any future updates will be listed below